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FPR2/ALXLipoxin A4 (LXA4) is an endogenous lipid mediator with potent anti-inﬂammatory actions but its role in infec-
tious processes is not well understood. We investigated the involvement of LXA4 and its receptor FPR2/ALX in
the septic inﬂammatory dysregulation. Pneumosepsis was induced in mice by inoculation of Klebsiella
pneumoniae. LXA4 levels and FPR2/ALX expression in the infectious focus as well as the effects of treatment
with receptor agonists (LXA4 and BML-111) and antagonists (BOC-2 and WRW(4)) in early (1 h) and late
(24 h) sepsis were studied. Sepsis induced an early increase in LXA4, FPR2/ALX lung expression, local and sys-
temic infection and inﬂammation, and mortality. Treatment with BOC-2 in early sepsis increased leukocyte mi-
gration to the focus, and reduced bacterial load and dissemination. Inhibition of 5- and 15-lipoxygenase in early
sepsis also increased leukocyte migration. Early treatment with WRW(4) and BOC-2 improved survival. Treat-
ment with authentic LXA4 or BML-111 in early sepsis decreased cell migration and worsened the infection. In
late sepsis, treatment with BOC-2 had no effect, but LXA4 improved the survival rate by reducing the excessive
inﬂammatory response, this effect being abolished by pretreatment with BOC-2. Thus, the anti-inﬂammatory
and pro-resolution mediator LXA4 and its receptor FPR2/ALX levels were increased in the early phase of sepsis,
contributing to the septic inﬂammatory dysregulation. In addition, LXA4 has a dual role in sepsis and that its ben-
eﬁcial or harmful effects are critically dependent on the time. Therefore, a proper interference with LXA4 system
may be a new therapeutic avenue to treat sepsis.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Sepsis is a disease with rising incidence and presenting a high
mortality rate of about 50% [1]. One of the major causes of sepsis is
pneumonia, responsible for almost half of all sources of infection
[1,2].
Sepsis involves two distinct, non-sequential and non-exclusive
phases known as the systemic inﬂammatory response and the com-
pensatory anti-inﬂammatory response [3]. Survival in sepsis is
inﬂuenced by the intensity of these phases as well as by the correct
balance between them. When this balance is lost, the host is no lon-
ger able to limit the infection or to keep the inﬂammatory insult
within limits. The result is the spreading of the infection and/or aormyl peptide receptor-2; AhR,
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rights reserved.dysregulation of the inﬂammatory response, affecting multiple or-
gans and causing irreversible damage and death. The dysregulation
of the inﬂammatory response in sepsis is associated with an exacer-
bated production of both pro- and anti-inﬂammatory mediators.
The production/release of these mediators in inadequate amounts
and/or timing compromises the ability of the host to mount or
maintain a proper inﬂammatory response. Indeed, the release of
anti-inﬂammatory mediators impairs the host response against in-
fection [4].
Lipoxins, particularly lipoxin A4 (LXA4), are anti-inﬂammatory
and pro-resolution mediators derived from the arachidonic acid
biosynthesized by twomain pathways, bothmediated by lipoxygenases
(LO). The ﬁrst pathway involves lipoxygenation of arachidonic acid by
15-LO in epithelial cells and monocytes, or by 5-LO in neutrophils [5].
The second pathway involves interactions of platelets and leukocytes
by transcellular conversion of the 5-LO epoxide product leukotriene to
LXA4 by the activity of 12-LO in platelets [6].
The actions of LXA4 are mediated through its binding to FPR2/ALX
membrane receptor or to the nuclear aryl hydrocarbon receptor
(AhR) [7,8]. FPR2/ALX has been described as the main receptor re-
sponsible for the in vivo anti-inﬂammatory actions of LXA4 [9,10].
The anti-inﬂammatory role of the FPR2/ALX receptor is well known,
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this G-protein-coupled receptor [11].
LXA4 exhibits a wide range of anti-inﬂammatory and pro-resolution
effects, including the ability to reduce vascular permeability, to impair
the entry of new neutrophils into sites of inﬂammation and to promote
the non-phlogistic inﬁltration of monocytes into the site of injury
[12–14]. LXA4 and its analogs exhibit protective roles in several experi-
mental inﬂammatory conditions, such as arthritis [15], cystic ﬁbrosis
[16], uveitis [17] and edema [18].
On the other hand, the role of LXA4 in infectious processes is not
well understood, since the beneﬁts of anti-inﬂammatory mechanisms
are difﬁcult to evaluate during an active infection. For instance, in
Mycobacterium tuberculosis infection high levels of LXA4 were associ-
ated with increase in pathogen replication, being the inhibition of LXA4
biosynthesis beneﬁcial to the host [19]. In contrast, mice succumbed to
Toxoplasma gondii infection in the absence of LXA4 because of an exac-
erbated pro-inﬂammatory response despite the reduction in parasite
number [20].
Therefore, we aimed to investigate the role of LXA4 and the FPR2/ALX
receptor in Klebsiella pneumoniae-induced sepsis and their involve-
ment in the dysregulation of inﬂammatory process that occurs in
this pathology.
2. Material and methods
2.1. Animals
Male Swiss mice (weighing 35–40 g) were housed in a temperature-
and light-controlled room (23 ± 2 °C; 12 h light/dark cycle), with free
access to water and food. The University Institutional Ethics Committee
for Animal Care and Use (CEUA) approved all procedures.
2.2. Bacterial inoculum and pneumosepsis induction
The bacterium used was K. pneumoniae— ATCC 700603 (American
Type Culture Collection, Rockville, MD). Pneumosepsis was induced
as previously described [21]. Brieﬂy, bacteria were made pathogenic
by 10 passages in C57-Bl6 mice. Before each experiment, individual
aliquots were washed twice with sterile Dulbecco's PBS (in mM 137
NaCl, 2.7 KCl, 1.5 KH2PO4, and 8.1 NaHPO4; pH 7.4), suspended in
Brain Heart Infusion broth and incubated for 18 h at 37 °C. The broth
was then centrifuged and the resultant pellet was washed twice with
sterile PBS. Bacterial concentrationwas determined by light absorbance
at 600 nm and compared to a standard curve. Mice were anesthetized
with tribromoethanol and ketamine (375/25 mg/kg, i.p.) and placed
in supine position. Under aseptic conditions, a 5 mm vertical inci-
sion was made in the frontal neck, the trachea was identiﬁed and
0.05 mL of either sterile PBS (sham-inoculated) or bacterial suspen-
sion (pneumosepsis) was injected into the trachea. Based on previ-
ous experiments, the number of viable bacteria inoculated was
4 × 108 CFU. The skin was closed with surgical suture. Animals received
30 mL/kg of sterile warm PBS subcutaneously. Until anesthesia recovery,
animals were maintained at 37 °C in their cages, and afterward they
were housed in a temperature- and light-controlled room as described
above.
2.3. Flow cytometry
To recover intrapulmonary inﬂammatory cells, 1 mL of sterile PBS
was instilled into the lungs through the trachea, and bronchoalveolar
lavage (BAL) was aspirated back. This procedure was repeated 3 times.
BAL samples were evaluated only when the volume recovery was
greater than 80%. Brieﬂy, BAL cells were obtained 6 and 24 h after
bacterial inoculation and incubated with rabbit anti-mouse FPR2
(cloneM-73; Santa Cruz Biotechnology, CA, USA) and various combi-
nations of ﬂuorochrome-conjugated rat anti-mouse mAbs speciﬁcfor CD11b-APC (integrin αM chain, Mac-1α chain; clone M1/70),
CD11c-PE-Cy7 (integrin αX; clone HL3), Gr-1-PE (Ly-6G and Ly-6C;
clone RB6-8C5) (all from BD Pharmingen, NJ, USA), and F4/80 eFluor®
450 (panmacrophage marker; clone BM8, eBioscience) for 1 h in FACS
buffer containing 0.5 mg/mL anti-mouse FcγIII/II receptor (clone 2.4G2;
BD Pharmingen). Samples were washed and the ﬁnal staining was
made with Alexa Fluor 488-conjugated anti-rabbit IgG (Invitrogen, UK).
Data were collected using a FACSCanto II with FACSDiva software and
data were analyzed with Flowjo software (Tree Star, Ashland, OR, USA).
Depending on the number of cells available, 30,000 to 50,000 events
per sample were analyzed.
2.4. Immunoﬂuorescence microscopy
Six and 24 h after infection, animals were anesthetized as above
and perfused through the heart with saline (0.9% NaCl) followed by
4% paraformaldehyde ﬁxative solution. The trachea was exposed and
cannulated; lungs were inﬂated with the same ﬁxative solution, re-
moved from the animal and placed in ﬁxative for 24 h. Then, lungs
were inﬂated with 25% (v/v) optimal cutting temperature freezing
medium (OCT; Tissue Tek®) in 20% sucrose in PBS, and embedded for
frozen sectioning. Sections (5 μm thick) were obtained using a cryostat
(Leica, Germany), mounted on gelatin-coated slides and blocked with
5% fetal bovine serum in PBS for 1 h. Then, slices were incubated with
rabbit polyclonal anti-FPR2 Ab (1:100, Santa Cruz Biotechnology, CA,
USA) overnight at 4 °C. Subsequently, slices were washed three times
with PBS and incubated with Alexa Fluor 488-conjugated anti-rabbit
IgG (1:1000, Invitrogen, UK) for 1 h at room temperature and washed
three times with PBS. Coverslips were mounted on the slides using
Gel Mount™ aqueous mounting medium (Sigma-Aldrich, St Louis,
MO, USA), and examined by ﬂuorescence microscopy (Olympus BX41,
Olympus, Tokyo, Japan). Images were captured using Q-capture Pro 5.1
(Q-imaging). Values were expressed as arbitrary ﬂuorescence intensity
relative to control conditions andwere quantiﬁed using ImageJ software.
2.5. Leukocyte counts
Total cell numbers were determined with a hemocytometer and
differential counts were determined on Cytospin smears stained with
rapid Panoptic stain (Laborclin, Pinhais, PR, Brazil). Themain cell popula-
tion in septic animalswas polymorphonuclear cells, butwe have also ob-
served a substantial number of immature myeloid cells with a ring-like
nucleus. Therefore, cell counts were divided in polymorphonuclear neu-
trophils, mononuclear cells and immature myeloid cells.
2.6. Quantiﬁcation of bacterial CFUs
Hearts and spleens were aseptically harvested, placed in 200 μL of
sterile PBS, and homogenized. BAL was also obtained under sterile
conditions and was diluted serially in sterile PBS. Ten microliters of
each dilution or tissue homogenate was aseptically plated and cul-
tured on Mueller-Hinton agar dishes at 37 °C. After 24 h, CFU were
counted and results were expressed as log CFU.
2.7. Determination of LXA4, cytokine, lactate and creatinine levels
Blood and BAL samples were obtained, centrifuged at 1200 g for
10 min at 4 °C, the plasma or supernatant was saved. The measurement
of LXA4 was done after extraction and assay according to the
manufacturer's recommendations using a commercially available
enzyme-linked immunosorbent assay kit (Oxford Biomedical Research,
Michigan, USA). Plasma cytokines TNF-alpha and IL-1beta were mea-
sured according to the manufacturer's recommendations using commer-
cially available enzyme-linked immunosorbent assay kits (PeproTech
Inc., New Jersey, USA). Plasma levels of lactate and creatinine were
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Fig. 1. LXA4 levels in mice pneumosepsis. Mice received 4 × 108 CFU of K. pneumoniae
(sepsis) or PBS (sham) intra-tracheally. Six and 24 h after injection BAL was obtained
and assayed for LXA4. Each bar represents the mean ± SEM of 6–8 animals. Statistical
analysis was performed using two-way ANOVA followed by Bonferroni's post hoc test.
*p b 0.05 compared to sham group. The experiment was repeated independently
twice.
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Brazil).
2.8. Experimental design
Animals were injected with K. pneumoniae and 6 or 24 h after,
LXA4 levels, ﬂow cytometry and immunoﬂuorescence microscopy
studies were performed as described. In the remaining experiments
(Figs. 4 to 8), animals were treated with the FPR2/ALX antagonist,
N-t-Boc-Phe-Leu-Phe-Leu-Phe (BOC-2; MP Biomedicals, Solon, OH, USA;
10 μg/kg; i.p.), or with the agonists, 5(S),6(R),7-trihydroxyheptanoic
acid methyl ester, a LXA4 analog (BML-111; Cayman Chemical Company,
Ann Harbor, MI, USA; 100 μg/kg; i.p.), or 5(S),6(R)-Lipoxin A4 (LXA4;
Cayman Chemical Company, Ann Harbor, MI, USA; 2.5 μg/kg; i.p.) 1 h
(early treatment) or 24 h (late treatment) after infection, as indicated in
ﬁgure legends. Then, 6 h (in early treatment) or 36 h (in late treatment)
after infection, BAL, blood and tissues were obtained for analysis. A group
of animals were treated with the antagonist BOC-2 (10 μg/kg; i.p.) 0.5 h
before the late treatment with LXA4. Survival experiments after early
and late treatmentswere also performed. Additionally, a group of animals
were pre-treated (1 h before infection) with the 15-LO inhibitor, PD
146176 (PD; 1 mg/kg; i.p.; Tocris Bioscience, Bristol, UK) or with the
5-LO inhibitor, BWA4C (BW; 10 mg/kg; i.p.; Wellcome Research Labora-
tories, London, UK) and BAL cells were evaluated 6 h after infection.
Another group of animals received WRW(4) (1 mg/kg; i.p.; American
Peptide Company, Inc., Sunnyvale, CA, USA) 1 h after infection and surviv-
al rate was observed.
2.9. Statistical analysis
Data are expressed as mean ± SEM of n animals. Statistical signiﬁ-
cance was analyzed by one or two-way ANOVA followed by the appro-
priate post-hoc test as indicated in the Figure legends. Differences in
survival were determined with log rank test. A p value of less than
0.05 was considered signiﬁcant. Statistical tests were performed using
GraphPad Prism software (San Diego, CA, USA).
2.10. Materials
N-t-Boc-Phe-Leu-Phe-Leu-Phe (BOC-2) was purchased from MP
Biomedicals (Solon, OH, USA), 5(S),6(R)-lipoxin A4 and 5(S),6(R),7-
trihydroxyheptanoic acid methyl ester (BML-111) from Cayman Chem-
ical Company (Ann Harbor, MI, USA), WRW(4) from American Peptide
Company, Inc. (Sunnyvale, CA, USA), PD 146176 from Tocris Biosci-
ence (Bristol, UK) and BWA4C fromWellcome Research Laboratories
(Beckenham, Kent, UK). The ﬂuorochrome-conjugated rat anti-
mouse CD11b-APC (integrin αM chain, Mac-1α chain; clone M1/70),
CD11c-PE-Cy7 (integrin αX; clone HL3), Gr-1-PE (Ly-6G and Ly-6C;
clone RB6-8C5) and anti-mouse FcγIII/II receptor (clone 2.4G2) were
purchased all from BD Pharmingen (Franklin Lakes, NJ, USA), F4/80
eFluor® 450 (panmacrophage marker; clone BM8) from eBioscience
(San Diego, CA, USA); rabbit polyclonal anti-FPR2 Ab from Santa Cruz
Biotechnology (Santa Cruz, CA, USA) and Alexa Fluor 488-conjugated
anti-rabbit IgG from Invitrogen (Paisley, UK). Gel Mount™ aqueous
mounting medium was purchased from Sigma-Aldrich (St Louis, MO,
USA).
3. Results
3.1. LXA4 levels in the infectious focus
Six hours after sepsis induction, LXA4 levels were increased by 25%
in BAL of septic when compared to sham-inoculated animals (Fig. 1).
Twenty-four hours after, the levels of LXA4 in sham and septic animals
were similar. Plasma levels of LXA4 six and 24 h after surgerywere sim-
ilar in both groups (data not shown).3.2. LXA4 receptor (FPR2/ALX) expression in lung tissue and BAL cells
Pneumosepsis increased the expression of FPR2/ALX receptor in BAL
cells (Fig. 2) and in lung tissue (Fig. 3). Analysis of BAL showed an early
increase of FPR2/ALX receptor expression mainly in macrophages
(CD11c + CD11b + F4/80+ cells; Fig. 2, Panels A and D) and in an im-
mature myeloid CD11c+ CD11b+ Gr-1+ F4/80+ cell population
(Fig. 2, Panels B and E). For example, 24 h after the infection, the per-
centage of macrophages expressing FPR2/ALX from sham animals was
7.9 ± 0.7% versusmacrophages fromseptic animals 33.4 ± 7.3%. The im-
mature myeloid cells from sham animals expressing the receptor were
29.8 ± 2.9% and the percentage increased to 83.3 ± 4.2% in septic ani-
mals. Although the frequency (percentage) and the absolute number of
FPR2/ALX-positive neutrophils CD11c-CD11b+ Gr-1+ F4/80-increased
in septic animals, the mean ﬂuorescence intensity has not changed
(Fig. 2, Panels C and F). Lung infectionwith K. pneumoniae alsomodulated
the levels of FPR2/ALX receptor in lung epithelium. Its basal levels are low
in sham animals but the infection caused an increased expression ob-
served 6 h after inoculation and that increased further 24 h after sepsis
induction (Fig. 3).
3.3. Effect of FPR2/ALX agonists (LXA4 and BML-111) and antagonist
(BOC-2) on leukocyte migration in pneumosepsis
It is well described that LXA4-FPR2/ALX pathway has an important
role in reducing cell migration. The conﬁrmation of this effect in our
model was obtained by the treatment of animals 1 h after infection
with LXA4 and its analog BML-111, which reduced leukocyte migration
to the infectious focus (Fig. 4, Panels A–H). Moreover, since LXA4 levels
were increased in the beginning of sepsis (Fig. 1), the treatment with
the FPR2/ALX receptor antagonist BOC-2 1 h after infection signiﬁcantly
increased leukocyte migration to the infectious focus (Fig. 4, Panel I).
The newly inﬁltrating cells were essentially polymorphonuclear leu-
kocytes (Fig. 4, Panel J) and immature myeloid cells (ring-like cells;
Fig. 4, Panel K). Further, treatment of animals with the selective
15-lipoxygenase inhibitor PD146176 or with the 5-lipoxygenase in-
hibitor BWA4C also increased leukocyte migration (Fig. 5). No signif-
icant effect was observed after treating sham-inoculated animals
with BOC-2, BML-111, LXA4, BWA4C or PD 146176.
3.4. Effect of FPR2/ALX agonists (LXA4 and BML-111) and antagonist
(BOC-2) on bacterial load
Bacteria were found in BAL, spleen and heart homogenates of sep-
tic animals (Fig. 6) thus substantiating the spreading of infection. The
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Fig. 2. FPR2/ALX expression in BAL cells of sham and septic animals 6 h and 24 h after infection. The myeloid population of cells was gated on by forward scattering and side scat-
tering and a CD11c gate was determined for subsequent analyses (data not shown). Flow cytometry dot-plot of CD11c+ (A and B) and CD11c− (C) BAL cells gated on CD11b+ and
F4/80+ (A) or Gr-1+ (B and C) staining. Percentages, absolute numbers and representative histograms of (D) macrophages (CD11c+ CD11b+ F4/80+) (E) immature myeloid
cells (CD11c+ CD11b+ Gr-1+ F4/80+) and (F) neutrophils (CD11c-CD11b+ Gr-1+ F4/80−) that express FPR2/ALX are shown. Each bar represents the mean ± SEM of 3–5
animals. White and gray histograms are sham and septic animals respectively. Statistical analysis was performed using two-way ANOVA followed by Bonferroni's post hoc test.
*p b 0.05 compared to sham group. Results shown are representative of three independent experiments.
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sepsis worsened the infection process as we observed CFU increases
in BAL and heart (Fig. 6, Panels A and B). Mirroring this, BOC-2 treat-
ment reduced the bacterial load in the infectious focus and in remote
organs (Fig. 6, Panel C). There was no bacteria growth in samples of
sham animals and therefore, only the results of BAL are shown.3.5. Effect of FPR2/ALX agonists (LXA4 and BML-111) and antagonists
(BOC-2 and WRW4) on survival
Mortality by pneumosepsis was 60–70% within 72 h (Fig. 7). BOC-2
treatment in early sepsis (1 h after infection) reduced the mortality to
40% (Fig. 7, Panel A; squares), WRW(4) reduced it further to 15%
(Fig. 7, Panel A; inverted triangles) and treatment with LXA4 (Fig. 7,
Panel A; diamonds) or its analog BML-111 (Fig. 7, Panel A; triangles)
did not changemortality.When the antagonist BOC-2was administered
later in sepsis (24 h after infection), it failed to improve survival (Fig. 7,
Panel B; squares). Contrary, when the agonists LXA4 (Fig. 7, Panel B;
diamonds) or BML-111 (Fig. 7, Panel B; triangles) were administered
24 h after infection, the survival increased. The protection observed
with the late treatment with LXA4 was abolished when animals also re-
ceived the antagonist BOC-2 0.5 h before LXA4 (Fig. 7, Panel B, squares).
In sham groups (vehicle, BOC-2, WRW(4), BML-111 and LXA4) the sur-
vival was 100% (data not shown).3.6. Effect of FPR2/ALX agonist (LXA4) in the organ dysfunction and systemic
inﬂammation parameters
In order to investigate the beneﬁcial role of LXA4 in late sepsis, we
evaluated its effects in pro-inﬂammatory cytokine levels and organ
damage markers 36 h after infection (or 12 h after the treatment
with LXA4). Septic control animals exhibited an increase in plasma
lactate, creatinine and pro-inﬂammatory cytokines TNF-α and IL-1β
levels (Fig. 8). LXA4 treatment in late sepsis reduced the systemic in-
ﬂammation as judge by the lower levels of TNF-α (Fig. 8, Panel A) and
IL-1β (Fig. 8, Panel B). Moreover, animals treated with LXA4 presented
lower levels of lactate (Fig. 8, Panel C), and an improvement in renal con-
dition, shown by lower levels of plasma creatinine (Fig. 8, Panel D).
When animals received the antagonist BOC-2 before LXA4 treatment,
the levels of cytokines TNF-α and IL-1β were similar to sepsis control
group (Fig. 8, Panels A and B, respectively). Although not statistically
different, levels of lactate and creatinine of septic animals treated with
BOC-2+ LXA4 were higher when compared to sepsis LXA4 group
(Fig. 8, Panels C and D, respectively).
4. Discussion
The present work contributes with some important ﬁndings. The
ﬁrst is to show that there are temporal windows in sepsis in which
anti-inﬂammatory and pro-resolution agents may be beneﬁcial or
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Fig. 3. Immunoﬂuorescence of FPR2/ALX in lung tissue of sham and septic mice. Images from sham (A) and septic mice were obtained 6 (B) and 24 h (C) after bacterial inoculation.
FPR2/ALX is stained and images are representative of at least three experiments. Quantitative analysis of ﬂuorescence intensity of FPR2/ALX expression is shown (D). Statistical
analysis was performed using one-way ANOVA followed by Dunnett's post hoc test. *p b 0.05 compared to sham group.
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the infectious focus in the beginning of pulmonary sepsis and that
this early increase seems to contribute to the inappropriate response
of the host to the infection. The third ﬁnding that supports a harmful
role of LXA4 in the early sepsis is that the pharmacological inhibition
of FPR/ALX2 receptor impacts favorably on the survival of animals
bearing pneumosepsis. And ﬁnally, when administered in late sepsis,
LXA4 reduced the excessive inﬂammatory response and improved
survival.
In an infectious process like sepsis where the pathogens are viable
andmultiplying, dampening the inﬂammatory response can be danger-
ous to the host. LXA4, together with other mediators, has a relevant role
as anti-inﬂammatory and pro-resolution agent and seems to be an
important mediator of the compensatory anti-inﬂammatory response
that occurs in sepsis. However, the timing of production/effect of LXA4
is crucial for this beneﬁcial pro-resolution and anti-inﬂammatory role
[22]. Our data show that in the beginning of septic process, the increase
in LXA4 production/release in the infectious focus is detrimental to the
host, since the blockade of FPR2/ALX receptor with BOC-2 promoted
an increase in leukocyte migration, a better control of the infection
and a greater survival. Corroborating BOC-2 results, the treatment of
septic animals with the selective FPR2/ALX antagonistWRW(4) also in-
creased survival. Therefore, we suggest that LXA4 is detrimental when
produced early in sepsis since it appears to modulate the inﬂammatory
response in favor of the pathogen.
The idea that LXA4 may favor pathogens has been put forward by
others [10,19,23], but ours is the ﬁrst study to present this concept in
sepsis. To support this idea, we administered authentic LXA4 and its
analog BML-111 in the beginning of sepsis, and observed a worsening
in the infectious process, probably due to a reduction in leukocyte mi-
gration to the focus. In contrast, when the FPR2/ALX antagonist was
administered in early sepsis, when the LXA4 levels were high, BOC-2
increased leukocyte migration and reduced the infectious process.
Interestingly, the inhibition of 5-LO or 15-LO, the main enzymesresponsible by endogenous LXA4 biosynthesis, also increased leuko-
cyte number in the inﬂammatory focus.
BOC-2 treatment main effect was to increase neutrophil migration
to the focus. Although some studies show that neutrophils may be
harmful to the host [24], it is well described that local recruitment
of neutrophils to the site of infection increased the clearance of bacte-
ria and improved survival [25–27] especially in early sepsis [25].
Besides the augmented LXA4 levels,we have also observed an increase
in FPR2/ALX receptor levels in lungs and BAL cells of septic animals,
suggesting that FPR2/ALX has an important role in sepsis, strengthening
that the anti-inﬂammatory pathway is operative in the beginning of the
process. An interesting ﬁnding was the increase of FPR2/ALX expression
in macrophages (CD11c+ CD11b+ F4/80+) and in an immature popu-
lation of myeloid cells (CD11c+ CD11b+Gr-1+ F4/80+). These imma-
ture myeloid cells are a heterogeneous population with ring-shaped
nuclei and expand in nearly all inﬂammatory conditions (reviewed in
[28]). The increase of this cell population in sepsis has been already de-
scribed [29,30], but the expression of the anti-inﬂammatory receptor
FPR2/ALX in this population is a novel and interesting ﬁnding. Although
most of the studies show that these cells exhibit suppressor activities
[28,31] other studies suggest that the immaturemyeloid cellsmayprotect
the host from infection since they are involved in NOS-2, ROS [32,33], and
pro-inﬂammatory cytokine and chemokine production [29]. Moreover,
an interesting recent work shows that in early sepsis these cells have a
pro-inﬂammatory role and in late sepsis these same cells exhibit an
anti-inﬂammatory proﬁle [30]. LXA4 therefore seems to be a modulator
of this immature myeloid cell population, as it does with neutrophils,
since FPR2/ALX receptor was strongly expressed in these cells. The rela-
tionship between LXA4 pathway and this cell population was evidenced
by our results showing that LXA4 and BML-111 administered in early sep-
sis decreased whereas BOC-2 increased their numbers.
Conﬁrming that LXA4 early release seems to be harmful to the host
in sepsis, early BOC-2 orWRW(4) treatment improved survival where-
as the late administration of the antagonist waswithout effect. This is in
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Fig. 4. The effect of FPR2/ALX agonists (LXA4 and BML-111) and antagonist (BOC-2) on leukocyte migration to the infectious focus. One hour after sepsis induction, mice received
LXA4 (2.5 μg/kg, i.p.; Panels A–D), BML-111 (100 μg/kg, i.p.; Panels E–H), BOC-2 (10 μg/kg, i.p.; Panels I–L) or vehicle, and 6 h after inoculation BAL was obtained as detailed in
Methods section. Panels A, E and I: total leukocyte numbers; Panels B, F and J: polymorphonuclear counts; Panels C, G and K: ring-like immature myeloid cells; Panels D, H and
L: mononuclear counts. Data are expressed as mean ± SEM of 7–9 animals. Statistical analysis was performed using two-way ANOVA followed by Bonferroni's post hoc test.
*p b 0.05 when compared to sham group and #p b 0.05 when compared to septic group. The experiment was repeated independently at least three times.
288 R. Sordi et al. / International Immunopharmacology 17 (2013) 283–292linewith the LXA4 biosynthesis proﬁle, which is higher in the ﬁrst hours
after the infection, and with the importance of an early infection con-
trol. Interestingly, when LXA4 or its analogwas administered in late sep-
sis, animals were protected from death. Several reports show that LXA4
inhibits IL-1β production [34–36] and we observed that LXA4 treatment
in late sepsis reduced the excessive inﬂammatory response, as judged by
TNF-α and IL-1β levels reduction. Blockade of FPR2/ALX with BOC-2
prevented TNF-α and IL-1β reduction, suggesting that LXA4 effect is
mediated through FPR2/ALX. Moreover, LXA4 treatment in late sepsisimproved tissue perfusion and renal function and increased survival.
Corroborating the late sepsis results, a recent work shows that in rats
submitted to CLP (cecal ligation and puncture) LXA4 was beneﬁcial in
sepsis by reduction in tissue injury [37]. Moreover, another work using
CLP model shows that even by reducing the migration of leukocyte to
the infectious focus, the resolutionmediator resolving D2was protective
in sepsis by controlling the excessive inﬂammatory response [38].
Although LXA4 can also bind to the nuclear receptor AhR, FPR2/ALX
is the most important receptor responsible to LXA4 in vivo effects [9].
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Fig. 5. The effect of 15-lipoxygenase (PD146176) and 5-lipoxygenase (BWA4C) inhibitors on leukocyte migration to the infectious focus. One hour before sepsis induction, mice
received PD146176 (1 mg/kg, i.p.; Panels A–D), BWA4C (10 mg/kg, i.p.; Panels E–H) or vehicle, and 6 h after inoculation BAL was obtained as detailed in the Material and methods
section. Panels A and E: total leukocyte numbers; Panels B and F: polymorphonuclear counts; Panels C and G: ring-like immature myeloid cells; Panels D and H: mononuclear
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pared to sham group and #p b 0.05 when compared to septic group.
289R. Sordi et al. / International Immunopharmacology 17 (2013) 283–292Notwithstanding the observed increase in FPR2/ALX expression in lungs
and BAL cells and the fact that FPR2/ALX antagonism with BOC-2 im-
paired LXA4 effects, we cannot exclude AhR as a mediator of some of
the LXA4 effects. It is important to keep in mind that FPR2/ALX is a pro-
miscuous receptor and responds to numerous endogenous and exoge-
nous ligands besides LXA4 (reviewed in [39]). Although our data on theincrease in LXA4 levels in early sepsis and the effects of exogenous
LXA4, its analogs and antagonists are indeed suggestive that this media-
tor is important, the results ofWRW(4) and BOC-2 should be interpreted
in the context that we cannot completely rule out the possibility of FPR2
activation by ligands other than LXA4, either host- and/or pathogen-
derived, during infection.
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Fig. 7. The effect of FPR2/ALX agonists (LXA4 and BML-111) and antagonists (BOC-2 and
WRW4) on survival rate of septic mice. One hour (Panel A) after bacterial inoculation,
mice received LXA4 (2.5 μg/kg, i.p.; diamonds), BML-111 (100 μg/kg, i.p.; triangles), BOC-2
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were expressed as percent survival and are representative of two different experiments.
n = 10–15 per group.
290 R. Sordi et al. / International Immunopharmacology 17 (2013) 283–292Sepsis is a dynamic entity and exhibits temporal changes. An indi-
vidual in the beginning of the septic process is not the same after few
hours or fewdays. Themediators are distinct and the inﬂammatory pro-
cess changes over time. Corroborating other authors [40], our data indi-
cate that pro- or anti-inﬂammatory agents should be delivered at the
appropriate phase of sepsis to be beneﬁcial and not harmful to the
host. In the beginning of sepsis, the pro-inﬂammatory response should
be strong to control the pathogen, and in the end of the process, it shouldbe well controlled in order to not be harmful to the host. We are
showing here that the LXA4 production is triggered early in sepsis,
and the modulation of its action in this time is beneﬁcial to the host.
In addition, we have shown that at the end of the process, the
anti-inﬂammatory effects of LXA4 can avoid an exacerbated pro-
inﬂammatory response.5. Conclusion
Together, our results show that LXA4 is increased in the infectious
focus in the beginning of septic process, contributing to the dysregulation
of inﬂammatory responsewith beneﬁcial consequences to thepathogens.
The antagonism of FPR2/ALX receptor exhibited beneﬁcial effects to the
host, increasing leukocyte migration, reducing bacterial load and culmi-
nating with a survival increase. On the other hand, LXA4 administered
in late sepsis was beneﬁcial to the host because it controls the excessive
inﬂammatory response. These data suggest for the ﬁrst time that a re-
duction in LXA4 anti-inﬂammatory mechanisms in the beginning or its
administration in late periods could be an interesting therapeutic alter-
native in sepsis treatment.
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